Automated EuroFlow approach for standardized in-depth dissection of human circulating B-cells and plasma cells.

B-cell EuroFlow automated gating and identification approach multiparameter flow cytometry plasma cell standardization

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 28 07 2023
accepted: 29 09 2023
medline: 3 11 2023
pubmed: 2 11 2023
entrez: 2 11 2023
Statut: epublish

Résumé

Multiparameter flow cytometry (FC) immunophenotyping is a key tool for detailed identification and characterization of human blood leucocytes, including B-lymphocytes and plasma cells (PC). However, currently used conventional data analysis strategies require extensive expertise, are time consuming, and show limited reproducibility. Here, we designed, constructed and validated an automated database-guided gating and identification (AGI) approach for fast and standardized in-depth dissection of B-lymphocyte and PC populations in human blood. For this purpose, 213 FC standard (FCS) datafiles corresponding to umbilical cord and peripheral blood samples from healthy and patient volunteers, stained with the 14-color 18-antibody EuroFlow BIgH-IMM panel, were used. The BIgH-IMM antibody panel allowed identification of 117 different B-lymphocyte and PC subsets. Samples from 36 healthy donors were stained and 14 of the datafiles that fulfilled strict inclusion criteria were analysed by an expert flow cytometrist to build the EuroFlow BIgH-IMM database. Data contained in the datafiles was then merged into a reference database that was uploaded in the Infinicyt software (Cytognos, Salamanca, Spain). Subsequently, we compared the results of manual gating (MG) with the performance of two classification algorithms -hierarchical algorithm vs two-step algorithm- for AGI of the cell populations present in 5 randomly selected FCS datafiles. The hierarchical AGI algorithm showed higher correlation values vs conventional MG (r Our results show that compared to conventional FC data analysis strategies, the here proposed AGI tool is a faster, more robust, reproducible, and standardized approach for in-depth analysis of B-lymphocyte and PC subsets circulating in human blood.

Sections du résumé

Background
Multiparameter flow cytometry (FC) immunophenotyping is a key tool for detailed identification and characterization of human blood leucocytes, including B-lymphocytes and plasma cells (PC). However, currently used conventional data analysis strategies require extensive expertise, are time consuming, and show limited reproducibility.
Objective
Here, we designed, constructed and validated an automated database-guided gating and identification (AGI) approach for fast and standardized in-depth dissection of B-lymphocyte and PC populations in human blood.
Methods
For this purpose, 213 FC standard (FCS) datafiles corresponding to umbilical cord and peripheral blood samples from healthy and patient volunteers, stained with the 14-color 18-antibody EuroFlow BIgH-IMM panel, were used.
Results
The BIgH-IMM antibody panel allowed identification of 117 different B-lymphocyte and PC subsets. Samples from 36 healthy donors were stained and 14 of the datafiles that fulfilled strict inclusion criteria were analysed by an expert flow cytometrist to build the EuroFlow BIgH-IMM database. Data contained in the datafiles was then merged into a reference database that was uploaded in the Infinicyt software (Cytognos, Salamanca, Spain). Subsequently, we compared the results of manual gating (MG) with the performance of two classification algorithms -hierarchical algorithm vs two-step algorithm- for AGI of the cell populations present in 5 randomly selected FCS datafiles. The hierarchical AGI algorithm showed higher correlation values vs conventional MG (r
Conclusion
Our results show that compared to conventional FC data analysis strategies, the here proposed AGI tool is a faster, more robust, reproducible, and standardized approach for in-depth analysis of B-lymphocyte and PC subsets circulating in human blood.

Identifiants

pubmed: 37915569
doi: 10.3389/fimmu.2023.1268686
pmc: PMC10616957
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1268686

Informations de copyright

Copyright © 2023 Delgado, Fluxa, Perez-Andres, Diks, van Gaans-van den Brink, Barkoff, Blanco, Torres-Valle, Berkowska, Grigore, van Dongen and Orfao.

Déclaration de conflit d'intérêts

JvD, AO, AMB, MB, EB, MP and AH-D, are listed as co inventors on the EuroFlow patent “Means and methods for multiparameter cytometry-based leukocyte subsetting” NL2844751, filing date 5 November 2019, owned by the EuroFlow scientific consortium, which describes the flow cytometry panel used in this study, and RF and AO are listed as co inventors on the patent “Method of digital information classification” US 10,133,962 B2, filing date 9 June 2017 owned by Cytognos S.L. JvD and AO report to be chairmen of the EuroFlow Scientific Foundation, which receives royalties from licensed patents, which are collectively owned by the participants of the EuroFlow Consortium. These royalties are exclusively used for continuation of the EuroFlow collaboration and sustainability of the EuroFlow consortium. JvD and AO report an Educational Services Agreement and a Scientific Advisor Agreement from BD Biosciences San Joseé, CA; all related fees and honoraria are for the involved University Departments at University of Salamanca. AH-D, GG and RF are employees of Cytognos S.L. Salamanca Spain. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Références

Vaccines (Basel). 2020 Mar 20;8(1):
pubmed: 32244919
BMC Bioinformatics. 2009 Apr 09;10:106
pubmed: 19358741
Cytometry B Clin Cytom. 2010;78 Suppl 1:S47-60
pubmed: 20839338
Nat Rev Immunol. 2016 Jul;16(7):449-62
pubmed: 27320317
Curr Opin Immunol. 2015 Apr;33:64-9
pubmed: 25677584
Blood Rev. 2013 Jul;27(4):193-207
pubmed: 23845589
Front Immunol. 2019 Jun 13;10:1271
pubmed: 31263462
Immunol Res. 2014 May;58(2-3):218-23
pubmed: 24825775
Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):E2770-7
pubmed: 24979804
PLoS Comput Biol. 2014 Aug 28;10(8):e1003806
pubmed: 25167361
J Allergy Clin Immunol. 2022 Nov;150(5):1216-1224
pubmed: 35728653
Cytometry A. 2022 Nov;101(11):942-959
pubmed: 35593221
Cytometry A. 2018 Nov;93(11):1132-1140
pubmed: 30277649
Vaccines (Basel). 2022 Jan 18;10(2):
pubmed: 35214595
Front Immunol. 2021 Aug 30;12:731643
pubmed: 34527001
J Allergy Clin Immunol. 2018 Jun;141(6):2208-2219.e16
pubmed: 29505809
Front Immunol. 2020 Nov 02;11:584646
pubmed: 33224147
J Immunol Methods. 2019 Dec;475:112372
pubmed: 28965920
Trends Biotechnol. 2013 Jul;31(7):415-25
pubmed: 23746659
J Immunol Methods. 2019 Dec;475:112631
pubmed: 31306640
Annu Rev Anal Chem (Palo Alto Calif). 2019 Jun 12;12(1):411-430
pubmed: 30699035
J Allergy Clin Immunol. 2019 Sep;144(3):809-824
pubmed: 30826363
Leukemia. 2017 Oct;31(10):2094-2103
pubmed: 28104919
Front Immunol. 2022 Sep 14;13:935879
pubmed: 36189252
Front Immunol. 2023 May 19;14:1191992
pubmed: 37275858
Blood. 2017 Jan 19;129(3):347-357
pubmed: 27903527
Lupus Sci Med. 2023 Apr;10(1):
pubmed: 37012057
Cytometry A. 2020 Oct;97(10):1044-1051
pubmed: 32830910
Front Immunol. 2021 Jun 10;12:666953
pubmed: 34177905
J Immunol Methods. 2019 Dec;475:112662
pubmed: 31454495
Leukemia. 2012 Sep;26(9):1986-2010
pubmed: 22948490
Int J Lab Hematol. 2019 May;41 Suppl 1:56-62
pubmed: 31069980
Nat Biotechnol. 2011 Oct 02;29(10):886-91
pubmed: 21964415
J Immunol Methods. 2019 Dec;475:112684
pubmed: 31676343
Front Immunol. 2020 Feb 27;11:166
pubmed: 32174910
Cytometry A. 2015 Jul;87(7):636-45
pubmed: 25573116
Eur J Immunol. 2013 Nov;43(11):2797-809
pubmed: 24258910
Immunol Cell Biol. 2022 Nov;100(10):805-821
pubmed: 36218032
Leukemia. 2018 Dec;32(12):2701-2705
pubmed: 29930299
Cytometry A. 2021 Oct;99(10):1007-1021
pubmed: 33606354
Mod Pathol. 2021 Jan;34(1):59-69
pubmed: 32999413
Front Immunol. 2017 Mar 23;8:319
pubmed: 28386257
Eur J Immunol. 2020 Sep;50(9):1283-1294
pubmed: 32910469
Front Immunol. 2020 Dec 15;11:566732
pubmed: 33384685
Bioinformatics. 2015 Feb 15;31(4):606-7
pubmed: 25378466
Front Immunol. 2018 Apr 23;9:835
pubmed: 29740441
J Immunol Methods. 2019 Dec;475:112618
pubmed: 31181212
Haematologica. 2010 Jun;95(6):1016-20
pubmed: 20081059

Auteurs

Alejandro H Delgado (AH)

Cytognos SL, Salamanca, Spain.
Translational and Clinical Research Program, Centro de Investigación del Cáncer (CIC) and Instituto de Biología Molecular y Celular del Cancer (IBMCC), CSIC-University of Salamanca (USAL), Salamanca, Spain.

Rafael Fluxa (R)

Cytognos SL, Salamanca, Spain.

Martin Perez-Andres (M)

Translational and Clinical Research Program, Centro de Investigación del Cáncer (CIC) and Instituto de Biología Molecular y Celular del Cancer (IBMCC), CSIC-University of Salamanca (USAL), Salamanca, Spain.
Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.

Annieck M Diks (AM)

Department of Immunology (IMMU), Leiden University Medical Center (LUMC), Leiden, Netherlands.

Jacqueline A M van Gaans-van den Brink (JAM)

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands.

Alex-Mikael Barkoff (AM)

Institute of Biomedicine, University of Turku (UTU), Turku, Finland.

Elena Blanco (E)

Translational and Clinical Research Program, Centro de Investigación del Cáncer (CIC) and Instituto de Biología Molecular y Celular del Cancer (IBMCC), CSIC-University of Salamanca (USAL), Salamanca, Spain.
Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.

Alba Torres-Valle (A)

Translational and Clinical Research Program, Centro de Investigación del Cáncer (CIC) and Instituto de Biología Molecular y Celular del Cancer (IBMCC), CSIC-University of Salamanca (USAL), Salamanca, Spain.
Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.

Magdalena A Berkowska (MA)

Department of Immunology (IMMU), Leiden University Medical Center (LUMC), Leiden, Netherlands.

Georgiana Grigore (G)

Cytognos SL, Salamanca, Spain.

J J M van Dongen (JJM)

Translational and Clinical Research Program, Centro de Investigación del Cáncer (CIC) and Instituto de Biología Molecular y Celular del Cancer (IBMCC), CSIC-University of Salamanca (USAL), Salamanca, Spain.
Department of Immunology (IMMU), Leiden University Medical Center (LUMC), Leiden, Netherlands.

Alberto Orfao (A)

Translational and Clinical Research Program, Centro de Investigación del Cáncer (CIC) and Instituto de Biología Molecular y Celular del Cancer (IBMCC), CSIC-University of Salamanca (USAL), Salamanca, Spain.
Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH